Search Results - Macapinlac, Manuel

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

    A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advance... by Goel, Sanjay, Desai, Kavita, Macapinlac, Manuel, Wadler, Scott, Goldberg, Gary, Fields, Abbie, Einstein, Mark, Volterra, Fabio, Wong, Benny, Martin, Russell, Mani, Sridhar

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    A Phase I Safety And Dose Escalation Trial Of Docetaxel Combined With GEM®231, A Second Generation Antisense Oligonucleotide Targeting Protein Kinase A R1[alpha] In Patients With Advanced Solid Cancers

    A Phase I Safety And Dose Escalation Trial Of Docetaxel Combined With GEM®231, A Second Generation Antisense Oligonucleotide Targeting Protein Kinase A R1[alpha] In Patients With A... by Goel, Sanjay, Desai, Kavita, Macapinlac, Manuel, Wadler, Scott, Goldberg, Gary, Fields, Abbie, Einstein, Mark, Volterra, Fabio, Wong, Benny, Russell, Martin, Mani, Sridhar

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A Phase I Safety And Dose Escalation Trial Of Docetaxel Combined With GEM registered 231, A Second Generation Antisense Oligonucleotide Targeting Protein Kinase A R1 alpha In Patients With Advanced Solid Cancers

    A Phase I Safety And Dose Escalation Trial Of Docetaxel Combined With GEM registered 231, A Second Generation Antisense Oligonucleotide Targeting Protein Kinase A R1 alpha In Patie... by Goel, Sanjay, Desai, Kavita, Macapinlac, Manuel, Wadler, Scott, Goldberg, Gary, Fields, Abbie, Einstein, Mark, Volterra, Fabio, Wong, Benny, Martin, Russell, Mani, Sridhar

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers

    A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with adva... by Goel, Sanjay, Desai, Kavita, Macapinlac, Manuel, Wadler, Scott, Goldberg, Gary, Fields, Abbie, Einstein, Mark, Volterra, Fabio, Wong, Benny, Martin, Russell, Mani, Sridhar

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: